A Clinical Study to Characterize Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma for Utilization of Target Engagement and Pharmacodynamic Biomarkers in Future Phase I Trials
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Expression levels of beta-catenin mRNA from core needle biopsy (CNB) equivalents of resected HCC.
Visit 3, approximately 7 days after screening Visit 1.
No
United States: Institutional Review Board
0000-215
NCT01521780
April 2012
November 2012
Name | Location |
---|